Actively Recruiting

Phase 2
Age: 2Years - 75Years
All Genders
NCT07493538

MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

Led by Masonic Cancer Center, University of Minnesota · Updated on 2026-04-16

132

Participants Needed

1

Research Sites

463 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a Phase II study following subjects proceeding with Treosulfan (36g/m2) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion, with post-transplant cyclophosphamide (PTCy) at 40mg/kg, tacrolimus and MMF for GVHD prophylaxis.

CONDITIONS

Official Title

MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

Who Can Participate

Age: 2Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients aged 2 to 75 years
  • Karnofsky score 70% or higher if 5 years or older; Lansky play score 50 or higher if under 16 years
  • Donor match: 5/6 or 6/6 related donor, 5-8/8 HLA matched unrelated donor, or haplotype matched related donor
  • Adequate liver function (no decompensated liver failure, Child-Pugh A, AST/ALT less than 5 times upper limit)
  • Adequate kidney function (creatinine less than 2.0)
  • No decompensated congestive heart failure or uncontrolled arrhythmia
  • Left ventricular ejection fraction 40% or higher
  • Lung function (DLCO, FEV1, FVC) 40% or higher predicted and no oxygen requirement
Not Eligible

You will not qualify if you...

  • Pregnant or breastfeeding
  • Untreated or uncontrolled HIV infection
  • Untreated active serious infection
  • Active central nervous system malignancy
  • Chronic myeloid leukemia in blast crisis not in complete remission
  • Less than 3 months since prior myeloablative transplant

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Masonic Cancer Center at University of Minnesota

Minneapolis, Minnesota, United States, 55455

Actively Recruiting

Loading map...

Research Team

C

Christopher Graham, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here